Advancing Your Solid Tumor Trials With A Cutting-Edge Assay Portfolio

Cerba Research has conducted ~200 oncology trials in the past 5 years, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. Our central and specialty laboratories' expertise includes specialized assays such as next-generation sequencing, flow cytometry, immunohistochemistry, AI in image analysis, and NanoString. Notably, Cerba Research has played a pivotal role in the approval of 24 innovative oncology drugs for indications like breast and lung cancer.

Assay Portfolio: Our comprehensive solid tumor profiling assays support identification of DNA and RNA fusions implicated in various solid tumor types.

Oncology Trial Expertise: Cerba Research has extensive experience in conducting oncology trials, with a focus on solid tumors.

Cutting-Edge Technologies: We utilize cutting-edge technologies such as next-generation sequencing, flow cytometry, immunohistochemistry, AI in image analysis, and NanoString to support oncology research.

To learn more about Cerba Research and its capabilities, please access the full content.